The tissue plasminogen activator gene promoter: A novel tool for radiogenci gene therapy of the prostate?

Journal of Gene Medicine

Volumn 10, Issue 9, 2008, Pages 1032-1038

  Marignol, L ^a   Robson, T ^b   McCarthy, H O ^b   Worthington, J ^c   Murray, M M ^b   Hollywood, D ^a   Lawler, M ^a   Hirst, D G ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Gene therapy; Hypoxia; Prostate cancer; Radiation; Vasculature

Indexed keywords

GREEN FLUORESCENT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CELL TYPE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; EX VIVO STUDY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; NONHUMAN; NONVIRAL GENE THERAPY; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION EXPOSURE; RAT; REPORTER GENE; TAIL ARTERY; TREATMENT RESPONSE; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; RATS; TISSUE PLASMINOGEN ACTIVATOR; TRANSFECTION; TRANSGENES;

RATTUS;

EID: 52649092904     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1221     Document Type: Article

References (53)

1. Khuntia D, Reddy CA, Mahadevan A, et al. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer 2004; 100: 1283-1292.
2. D'Ambrosio DJ, Pollack A, Harris EE, et al. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 671-677.
3. Marignol L, Coffey M, Hollywood D, Lawler M. Radiation to control transgene expression in tumors. Cancer Biol Ther 2007; 6: 1005-1012.
4. McCarthy HO, Worthington J, Barrett E, et al. p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 2007; 14: 246-255.
5. Scott SD, Marples B, Hendry JH, et al. A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther 2000; 7: 1121-1125.
6. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-91.
7. Weichselbaum RR, Hallahan DE, Beckett MA, et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994; 54: 4266-4269.
8. Mezhir JJ, Smith KD, Posner MC, et al. Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther 2006; 13: 1-6.
9. Christy B, Nathans D. Functional serum response elements upstream of the growth factor-inducible gene zif268. Mol Cell Biol 1989; 9: 4889-4895.
10. Scott SD, Joiner MC, Marples B. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Ther 2002; 9: 1396-1402.
11. Aslan G, Cimen S, Yorukoglu K, et al. Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol Res Pract 2005; 201: 593-598.
12. Buttyan R, Ghafar MA, Shabsigh A. The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol 2000; 10: 415-420.
13. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J 2007; 9: E18-29.
14. Gao X, Kim KS, Liu D. Nonviral gene delivery: what we know and what is next. AAPS J 2007; 9: E92-104.
15. Wang Y, Yuan F. Delivery of viral vectors to tumor cells: extracellular transport, systemic distribution, and strategies for improvement. Ann Biomed Eng 2006; 34: 114-127.
16. Worthington J, Robson T, Murray M, et al. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther 2000; 7: 1126-1131.
17. Permica D, Holmes WE, Kohr WJ, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214-221.
18. Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-2919.
19. Cajot JF, Kruithof EK, Schleuning WD, et al. Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer 1986; 38: 719-727.
20. Kirchheimer J, Binder BR. Localization and immunological characterization of plasminogen activators in human prostate tissue. Haemostasis 1983; 13: 358-362.
21. Levin EG, Loskutoff DJ. Regulation of plasminogen activator production by cultured endothelial cells. Ann N Y Acad Sci 1982; 401: 184-194.
22. Meroni PL, Borghi MO, Raschi E, et al. Inflammatory response and the endothelium. Thromb Res 2004; 114: 329-334.
23. Pepper MS, Montesano R, Mandriota SJ, et al. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 1996; 49: 138-162.
24. Duffy MJ. Plasminogen activators and cancer. Blood Coagul Fibrinolysis 1990; 1: 681-687.
25. Miskin R, Reich E. Plasminogen activator: induction of synthesis by DNA damage. Cell 1980; 19: 217-224.
26. Boothman DA, Wang M, Lee SW. Induction of tissue-type plasminogen activator by ionizing radiation in human malignant melanoma cells. Cancer Res 1991; 51: 5587-5595.
27. Fujiwara J, Kimura T, Ayusawa D, et al. A novel regulatory sequence affecting the constitutive expression of tissue plasminogen activator (tPA) gene in human melanoma (Bowes) cells. J Biol Chem 1994; 269: 18558-18562.
28. Boothman DA, Lee IW, Sahijdak WM. Isolation of an X-ray-responsive element in the promoter region of tissue-type plasminogen activator: potential uses of X-ray-responsive elements for gene therapy. Radiat Res 1994; 138: S68-71.
29. Williams SG, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007; 68: 24-33.
30. Leborgne F, Fowler J. Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: nonrandomized contemporary comparison with standard fractionation. Int J Radiat Oncol Biol Phys 2008 [Epub ahead of print].
31. Mile EF, Lee WR. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol 2008; 18: 41-47.
32. Al-Salihi 0, Mitra A, Payne H. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy. Prostate Cancer Prostatic Dis 2006; 9: 370-373.
33. King CR, Lehmann J, Adler JR, et al. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat 2003; 2: 25-30.
34. Pawlicki T, Cotrutz C, King C. Prostate cancer therapy with stereotactic body radiation therapy. Front Radiat Ther Oncol 2007; 40:395-406.
35. Pawlicki T, Kim GY, Hsu A, et al. Investigation of linac-based image-guided hypofractionated prostate radiotherapy. Med Dosim 2007; 32: 71-79.
36. Worthington J, McCarthy HO, Barrett E, et al. Use of the radiation-inducible WAFl promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 2004; 6: 673-680.
37. Fukunaga N, Burrows HL, Meyers M, et al. Enhanced induction of tissue-type plasminogen activator in normal human cells compared to cancer-prone cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1992; 24: 949-957.
38. Gottschalk AR, Roach M III. The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials. Br J Cancer 2004; 90: 950-954.
39. Freytag SO, Stricker H, Peabody J, et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007; 15: 636-642.
40. Kinoh H, Inoue M. New cancer therapy using genetically-engineered oncolytic Sendai virus vector. Front Biosci 2008; 13:2327-2334.
41. Garanger E, Boturyn D, Dumy P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem 2007; 7: 552-558.
42. Jung M, Zhang Y, Dimtchev A, et al. Interstitial gene delivery in human xenograft prostate tumors using titanium metal seeds. Mol Cancer Ther 2004; 3: 655-659.
43. Bazan-Peregrino M, Seymour LW, Harris AL. Gene therapy targeting to tumor endothelium. Cancer Gene Ther 2007; 14: 117-127.
44. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621.
45. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102-111.
46. Moeller BJ, Cao Y, Li CY, et al. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5: 429-441.
47. Koukourakis MI, Abatzoglou I, Touloupidis S, et al. Biological dose volume histograms during conformal hypofractionated accelerated radiotherapy for prostate cancer. Med Phys 2007; 34: 76-80.
48. Loblaw DA, Cheung P. External beam irradiation for localized prostate cancer-the promise of hypofractionation. Can J Urol 2006; 13(Suppl 1): 62-66.
49. Lee WR. Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction. Future Oncol 2007; 3: 649-654.
50. Vicini F, Vargas C, Gustafson G, et al. High dose rate brachytherapy in the treatment of prostate cancer. World J Urol 2003; 21: 220-228.
51. Hoskin PJ. High dose rate brachytherapy boost treatment in radical radiotherapy for prostate cancer. Radiother Oncol 2000; 57: 285-288.
52. Schainfeld RM. Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature. Catheter Cardiovasc Interv 2002 ; 56: 421-431.
53. Van Limbergen E, Trepuraneni P. Is this the swan song of endovascular brachytherapy? Radiother Oncol 2007; 82: 1-4.